SOM230: A new therapeutic modality for Cushing's disease

被引：0
|
作者：
Lewis, Ian [1 ]
Pless, Janos [2 ]
Kneuer, Rainer [1 ]
Silva, Antonio [2 ]
Hoyer, Daniel [2 ]
Weckbecker, Gisbert [2 ]
Bruns, Christian [2 ]
Schmid, Herbert A. [2 ]
机构：
[1] Novartis Inst Biomed Res, Dept Exploratory Med Chem Global Discovery Chem, CH-4002 Basel, Switzerland
[2] Novartis Inst Biomed Res, Dept Autoimmune Oncol & Nervous Syst Res, CH-4002 Basel, Switzerland
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2013年 / 246卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
164-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SOM230: A New Therapeutic Modality for Cushing's Disease
    Lewis, Ian
    Schmid, Herbert A.
    Kneuer, Rainer
    Hoyer, Daniel
    Silva, Antonio P.
    Weckbecker, Gisbert
    Bruns, Christian
    Pless, Janos
    CHIMIA, 2014, 68 (7-8) : 483 - 484
  • [2] SOM230: A new therapeutic modality for Cushing's disease
    Lewis, Ian
    Pless, Janos
    Kneuer, Rainer
    Hoyer, Daniel
    Silva, Antonio P.
    Weckbecker, Gisbert
    Bruns, Christian
    Schmid, Herbert A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [3] SOM230 in Cushing's disease complicated by poorly controlled diabetes mellitus
    Fiorentino, C.
    Motta, C.
    Wolosinska, D. T.
    Monti, S.
    Mori, F.
    Toscano, V.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (09) : 731 - 732
  • [4] SOM230 in Cushing’s disease complicated by poorly controlled diabetes mellitus
    C. Fiorentino
    C. Motta
    D. T. Wolosinska
    S. Monti
    F. Mori
    V. Toscano
    Journal of Endocrinological Investigation, 2011, 34 : 731 - 732
  • [5] Effect of SOM230 (Pasireotide) on Corticotropic Cells: Action in Dogs with Cushing's Disease
    Castillo, Victor
    Theodoropoulou, Marily
    Stalla, Johanna
    Gallelli, Maria Florencia
    Cabrera-Blatter, Maria Fernanda
    Haedo, Mariana R.
    Labeur, Marta
    Schmid, Herbert A.
    Stalla, Guenter K.
    Arzt, Eduardo
    NEUROENDOCRINOLOGY, 2011, 94 (02) : 124 - 136
  • [6] Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease
    Cukier, Kimberly
    Tewari, Reena
    Kurth, Fabian
    Schmid, Herbert A.
    Lai, Clinton
    Torpy, David J.
    CLINICAL ENDOCRINOLOGY, 2009, 71 (02) : 305 - 307
  • [7] UFC response is related to pasireotide (SOM230) plasma concentrations in patients with Cushing's disease
    Maldonado, Mario
    Boscaro, Marco
    Zhang, Yilong
    Sen, Kapildeb
    Schoenherr, Ulrike
    Findling, James
    ENDOCRINE JOURNAL, 2010, 57 : S514 - S514
  • [8] Pasireotide (SOM230): Mechanism of Action in Acromegaly, Cushing's Disease and GEP-NETs
    Schmid, H. A.
    Silva, A. P.
    van Vugt, H. H.
    Gadelha, M.
    PROCEEDINGS OF THE 13TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2008, : 467 - +
  • [9] Pasireotide (SOM230): a novel pituitary-targeted medical therapy for the treatment of patients with Cushing's disease
    Moloney, Kelley J.
    Mercado, Jennifer U.
    Ludlam, William H.
    Mayberg, Marc R.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (05) : 491 - 502
  • [10] The role of SOM230 in acromegaly
    van der Hoek, J
    van der Lelij, AJ
    Feelders, RA
    de Herder, WW
    Uitterlinden, P
    Boerlin, V
    Bruns, C
    Poon, KW
    Lewis, I
    Weckbecker, G
    Krahnke, T
    Hofland, LJ
    Lamberts, SW
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152
12345